Entegris Free cash flow increased by 5.6% to $141.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 336.7%, from $32.40M to $141.50M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 20.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $40.08M | $100.62M | $39.34M | -$20.62M | $0.00 | $18.79M | -$104.46M | $17.88M | $10.97M | $129.34M | $29.51M | $80.60M | $51.90M | $115.00M | $68.60M | $32.40M | $47.00M | $182.80M | $134.00M | $141.50M |
| QoQ Change | — | +151.0% | -60.9% | -152.4% | +100.0% | — | -655.8% | +117.1% | -38.7% | >999% | -77.2% | +173.1% | -35.6% | +121.6% | -40.3% | -52.8% | +45.1% | +288.9% | -26.7% | +5.6% |
| YoY Change | — | — | — | — | -100.0% | -81.3% | -365.5% | +186.7% | — | +588.3% | +128.3% | +350.8% | +373.2% | -11.1% | +132.5% | -59.8% | -9.4% | +59.0% | +95.3% | +336.7% |